The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
I am a clinical researcher determining: a) the role of altered airway structure, particularly airway smooth muscle and extracellular matrix, in asthma and COPD; and b) the prevalence of, and risk factors for, respiratory disease in general populations.
Identification Of Brain Regions Involved In The Regulation Of Coughing
Funder
National Health and Medical Research Council
Funding Amount
$431,146.00
Summary
Cough is a symptom of more than 100 clinical conditions of the respiratory system, and is the most common reason that people seek medical advice. However, currently available cough suppresant drugs are at best only modestly effective at treating cough disorders. In this study we aim to better understand how the brain regulates coughing in the hope to identify new therapeutic targets for relieving cough.
Developing A Standard Dyspnea Challenge To Explore Mechanisms And Therapies In Clinical Populations
Funder
National Health and Medical Research Council
Funding Amount
$454,383.00
Summary
COPD is Australia's most burdensome respiratory disease with over 200,000 new cases diagnosed each year. Shortness of breath is a cardinal feature of this disease.This project will examine the mechanisms of this symptom in patients with chronic lung disease. Four studies will be completed in total, each exploring different factors that may contribute to shortness of breath observed in patients. This research is likely to lead to improved management of this distressing condition into the future.
Endothelial Development From Pluripotent Stem Cells As A Means To Study Pathology In Pulmonary Artery Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$613,311.00
Summary
Pulmonary artery hypertension (PAH) is a fatal disease primarily affecting young adults. It is caused by a defect in cells that form the vessel that carries blood from the heart to the lungs. We will use stem cells made from the skin of PAH patients to examine why the blood vessel cells from these patients fail to function normally.
Serum Mesothelin-related Protein As An Early Marker Of Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$354,750.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. It is expected to cost communities hundreds of billions of dollars in compensation. This disease is usually already quite advanced by the time a patients presents to a doctor with symptoms so we have been working on methods of early detection. This project studies a new, exciting method of diagnosis using blood levels of a molecule called 'SMRP'. Late l ....The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year and its incidence is increasing. It is expected to cost communities hundreds of billions of dollars in compensation. This disease is usually already quite advanced by the time a patients presents to a doctor with symptoms so we have been working on methods of early detection. This project studies a new, exciting method of diagnosis using blood levels of a molecule called 'SMRP'. Late last year we published a paper in the prestigious journal Lancet showing that SMRP was a good test to help diagnose mesothelioma and this became a lead news item around the world because of widespread concern about this disease. In those studies we found strong clues that this test was very sensitive and could detect mesothelioma a year or so before a patient develops symptoms. In this grant we will evaluate whether this test could be useful for screening asbestos-exposed individuals for early detection of this cancer. We will also study ways of improving the test using laboratory methods. This would provide a foundation for studies aimed at determining if early treatment could improve patient survival.Read moreRead less
Diagnostic Markers For Malignant Mesothelioma And Other Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$467,315.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of individuals per year. We have been working on improving the tests available to detect this cancer and to follow the course of the disease with the aim of reducing patients' anxiety and health-care costs.
Investigatin The Causes Of Failed Efferocytosis In COPD-emphysema With A View To Identifying Novel Theraputic Targets
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
COPD is a leading cause of death. Smoking is the major cause of COPD and many sufferers are left with permanent damage and need ongoing treatment even after smoking cessation. Current treatments for COPD generally have limited efficacy. The project will identify the reason for the large number of dying cells and defective clearance of these cells that we have identified in the airways in COPD and study novel treatments that we hope will improve the health and well being of those with COPD.
Long-lasting Correction Of The Basic Defect In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$458,500.00
Summary
The airway disease caused by the genetic disease cystic fibrosis (CF) is not yet preventable. Current treatments can only limit the gradually-increasing lung disease and is costly. Our new gene therapy technique introduces a correcting gene into affected airway cells, and it has already worked in the first tests in mice bred with CF. Airways in mice are used to test whether the effect is reliable, effective, and lasts long enough to be useful. The gene is introduced into the airway using special ....The airway disease caused by the genetic disease cystic fibrosis (CF) is not yet preventable. Current treatments can only limit the gradually-increasing lung disease and is costly. Our new gene therapy technique introduces a correcting gene into affected airway cells, and it has already worked in the first tests in mice bred with CF. Airways in mice are used to test whether the effect is reliable, effective, and lasts long enough to be useful. The gene is introduced into the airway using special virus delivery-particles, after conditioning the airway to make it receptive to the particles. The method works in normal mice and in CF mice; it gives long lasting gene transfer from a single dose and seems to affect all airway cell types. The gene transfer may also be occurring in airway stem cells, i.e. the mother cells from which grow all the cells of the airway surface. Until now, no-one else has been able to produce prolonged gene transfer in this way, nor arrange gene transfer into stem cells in live airways. There are now a number of things that we must investigate before we could conduct safety and effectiveness trials in larger animals, or consider moving into clinical trials in humans. We need to understand exactly how our conditioning agent works and is it safe; measure how long the gene correction can last actually in our animals; decide if we can we re-dose animals (if needed) without losing effectiveness because of inflammation or immune responses that might occur; and decide how important the airway stem cells are in producing the length of the gene transfer. Because it has been difficult to measure gene correction in CF airways, we will also test new ways we have developed to measure how well the gene correction works in CF airways. The findings of this project will allow us to develop our method to where we can test it in larger animals, to provide a strong, long-lasting gene correction that will be safe for testing in human clinical trials.Read moreRead less
Is MUC1 A Viable Therapeutic Target For Patients With The Asbestos-induced Tumour Malignant Mesothelioma?
Funder
National Health and Medical Research Council
Funding Amount
$465,068.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. We are investigating the use of a specific marker, called MUC1, to improve mesothelioma diagnosis. Improved diagnosis will reduce the time taken to commence treatment. It will also reduce hospital costs and the number of surgical procedures a patients must undergo.